MEDIVIR, INTERIM REPORT, 1 January – 30 September 2005

• A phase IIa study on MIV-210 against multiresistant HIV began in September. • A Candidate drug (CD) was designated on the Cathepsin K project against osteoporosis in May. • BI (Boehringer Ingelheim) concluded its research collaboration with Medivir on the HIV compound MIV-310 (polymerase inhibitor) in March. Medivir has decided to prioritize its protease projects, and accordingly, will not assign in-house resources to MIV-310 until further notice. • Consolidated net sales were SEK 41.0 (18.4) m in the period. • The loss after tax was SEK -112.6 (-132.3) m; earnings per share were SEK -8.72 (-12.31). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Financial Statement will be published on 16 February 2006 The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m. Medivir’s financial reports are available from its Website, from these dates.

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


Documents & Links